{"disease":{"id":"relapsed-and-refractory-b-cell-lymphoma","name":"relapsed and refractory b cell lymphoma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04609241","title":"CD79b CAR-T Cell Therapy for Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia and B-cell Non-Hodgkin's Lymphoma","phase":"EARLY_PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":72,"lead_sponsor_name":"Zhejiang University","has_results":false},{"nct_id":"NCT05585996","title":"Exploratory Clinical Study of CD19-targeted CAR-T and CAR-DC in the Treatment of Relapsed and Refractory B-cell Lymphoma","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":70,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT07055477","title":"A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04697940","title":"Decitabine-primed Tandem CD19/CD20 CAR T Cells Treatment in r/r B-NHL","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":33,"lead_sponsor_name":"Han weidong","has_results":false},{"nct_id":"NCT03376958","title":"Apatinib for Relapsed and Refractory Diffuse Large B Cell Lymphoma","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":32,"lead_sponsor_name":"Zhengzhou University","has_results":false},{"nct_id":"NCT04169932","title":"The Clinical Study of CD20 CAR-T Cells in Patients With Relapsed and Refractory B Cell Non-Hodgkin Lymphoma","phase":"EARLY_PHASE1","overall_status":"UNKNOWN","enrollment_count":20,"lead_sponsor_name":"Shanghai Longyao Biotechnology Inc., Ltd.","has_results":false},{"nct_id":"NCT06295549","title":"Targeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":11,"lead_sponsor_name":"The First Affiliated Hospital with Nanjing Medical University","has_results":false}],"total":7},"guidelines":[],"source":"Drug Landscape verified database"}